Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies

被引:2
作者
Lantz, Anna [1 ,2 ]
Haug, Erik Skaaheim [3 ]
Picker, Wolfgang [4 ]
Crippa, Alessio [1 ]
Jaderling, Fredrik [2 ,5 ]
Mortezavi, Ashkan [1 ]
Nordstrom, Tobias [1 ,6 ]
机构
[1] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden
[2] Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[3] Vestfold Hosp Trust, Sect Urol, Tonsberg, Norway
[4] Aleris Canc Ctr, Dept Radiol, Oslo, Norway
[5] Karolinska Univ Hosp, Dept Diagnost Radiol, Stockholm, Sweden
[6] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden
关键词
Prostate cancer; Prostate neoplasm; Prostate biopsy; Targeted biopsy; Magnetic resonance imaging; MRI; MAGNETIC-RESONANCE; CANCER RISK; DIAGNOSIS;
D O I
10.1007/s00345-020-03277-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose To describe the predictive value of information on previous benign biopsy for the outcome of MRI-targeted biopsies. Methods An exploratory analysis was conducted using data from a prospective, multicenter, paired diagnostic study of 532 men undergoing diagnostics for prostate cancer during 2016-2017. All men underwent 1.5 T MRI; systematic prostate biopsies; and MRI-targeted biopsies to MRI lesions with Prostate Imaging Reporting and Data System version 2, PI-RADS >= 3. The main outcome was numbers of detected prostate cancer characterized by grade group (GG) where GG >= 2 defined clinically significant cancer (csPCa). Results Men with previous biopsies had significantly more often negative MRI (26% vs. 17%,p < 0.05) compared to men without previous biopsies. Men with previous biopsies showed higher rates of benign biopsies (41% vs. 26%,p < 0.05) and lower rates of GG2 (17% vs. 30%,p < 0.05) and GG >= 3 (5% vs. 10%,p < 0.05) cancer. Biopsy-naive men had higher proportions of highly suspicious MRI lesions (PIRADS 5;p < 0.05) and a higher proportion of significant cancer in those lesions (p = 0.05). In multivariate regression analysis, a previous benign prostate biopsy was associated with less than half the odds of csPCa (OR 0.38; 95% CI 0.20-0.71). Conclusion In this large prospective multicenter trial, we showed that men with a previous prostate biopsy had higher proportions of MRIs without lesions and lower proportion of highly suspicious lesions than biopsy-naive men. Further, biopsy-naive men showed higher detection of clinically significant cancer when using MRI-targeted biopsies. Also, in the era of MRI-targeted biopsy strategies, biopsy history should be carefully considered in biopsy decisions.
引用
收藏
页码:1153 / 1159
页数:7
相关论文
共 50 条
  • [31] Optimal Method for Reporting Prostate Cancer Grade in MRI-targeted Biopsies
    Deng, Fang-Ming
    Isaila, Bogdan
    Jones, Derek
    Ren, Qinghu
    Kyung, Park
    Hoskoppal, Deepthi
    Huang, Hongying
    Mirsadraei, Leili
    Xia, Yuhe
    Melamed, Jonathan
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2022, 46 (01) : 44 - 50
  • [32] Comparison of Systematic, Targeted and Combined Prostate Biopsy: Our Clinical Outcomes
    Senoglu, Yusuf
    Taskiran, Arda Taskin
    Yuksel, Alpaslan
    Baba, Dursun
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2022, 21 (02): : 40 - 44
  • [33] Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis
    Choi, Young Hyo
    Kang, Min Yong
    Sung, Hyun Hwan
    Eon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Kim, Chan Kyo
    Park, Byung Kwan
    Lee, Hyun Moo
    CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : E19 - E25
  • [34] Modern aspects of targeted prostate biopsy
    Popov, S., V
    Orlov, I. N.
    Malevich, S. M.
    Sushina, I., V
    Grin', E. A.
    Gulko, A. M.
    Topuzov, T. M.
    Vyazovtsev, P. V.
    Chernysheva, D. Yu
    Neradovskiy, V. A.
    ONKOUROLOGIYA, 2021, 17 (01): : 153 - 158
  • [35] Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy
    Sadhna Verma
    Andrew B. Rosenkrantz
    Peter Choyke
    Steven C. Eberhardt
    Scott E. Eggener
    Krishnanath Gaitonde
    Masoom A. Haider
    Daniel J. Margolis
    Leonard S. Marks
    Peter Pinto
    Geoffrey A. Sonn
    Samir S. Taneja
    Abdominal Radiology, 2017, 42 : 346 - 349
  • [36] Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion?
    Stabile, Armando
    Sorce, Gabriele
    Barletta, Francesco
    Brembilla, Giorgio
    Mazzone, Elio
    Pellegrino, Francesco
    Cannoletta, Donato
    Cirulli, Giuseppe Ottone
    Gandaglia, Giorgio
    De Cobelli, Francesco
    Montorsi, Francesco
    Briganti, Alberto
    WORLD JOURNAL OF UROLOGY, 2023, 41 (11) : 3231 - 3237
  • [37] Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion?
    Armando Stabile
    Gabriele Sorce
    Francesco Barletta
    Giorgio Brembilla
    Elio Mazzone
    Francesco Pellegrino
    Donato Cannoletta
    Giuseppe Ottone Cirulli
    Giorgio Gandaglia
    Francesco De Cobelli
    Francesco Montorsi
    Alberto Briganti
    World Journal of Urology, 2023, 41 : 3231 - 3237
  • [38] Outcomes of combination MRI-targeted and transperineal template biopsy in restaging low-risk prostate cancer for active surveillance
    Chen, Kenneth
    Tay, Kae Jack
    Law, Yan Mee
    Aydin, Hakan
    Ho, Henry
    Cheng, Christopher
    Yuen, John Shyi Peng
    ASIAN JOURNAL OF UROLOGY, 2018, 5 (03) : 184 - 193
  • [39] Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest
    Yannick Cerantola
    Eléonore Haberer
    Jose Torres
    Mona Alameldin
    Samuel Aronson
    Mark Levental
    Franck Bladou
    Maurice Anidjar
    World Journal of Urology, 2016, 34 : 75 - 82
  • [40] The Role of Multiparametric MRI and MRI-targeted Biopsy in the Diagnosis of Radiorecurrent Prostate Cancer: An Analysis from the FORECAST Trial
    Light, Alexander
    Kanthabalan, Abi
    Otieno, Marjorie
    Pavlou, Menelaos
    Omar, Rumana
    Adeleke, Sola
    Giganti, Francesco
    Brew-Graves, Chris
    Williams, Norman R.
    Emara, Amr
    Haroon, Athar
    Latifoltojar, Arash
    Sidhu, Harbir
    Freeman, Alex
    Orczyk, Clement
    Nikapota, Ashok
    Dudderidge, Tim
    Hindley, Richard G.
    Virdi, Jaspal
    Arya, Manit
    Payne, Heather
    Mitra, Anita, V
    Bomanji, Jamshed
    Winkler, Mathias
    Horan, Gail
    Moore, Caroline M.
    Emberton, Mark
    Punwani, Shonit
    Ahmed, Hashim U.
    Shah, Taimur T.
    EUROPEAN UROLOGY, 2024, 85 (01) : 35 - 46